Skip to main content
Top
Published in: Diabetologia 2/2006

01-02-2006 | Short Communication

Paradoxical rise in serum adiponectin concentration in the face of acid-induced insulin resistance 13-cis-retinoic

Authors: H. A. Koistinen, A. Remitz, V. A. Koivisto, P. Ebeling

Published in: Diabetologia | Issue 2/2006

Login to get access

Abstract

Aims/hypothesis

We previously reported that treatment of acne with 13-cis-retinoic acid causes insulin resistance and disturbances in lipid metabolism resembling those of the insulin-resistance syndrome. It is not known whether this is associated with alterations in the concentrations of serum adiponectin, an insulin-sensitising hormone secreted by adipocytes.

Materials and methods

Eleven men (age 24±2 years, BMI 22.1±0.9 kg/m2) received 13-cis-retinoic acid (Roaccutan) treatment for acne for an average of 5 months. The insulin sensitivity of the subjects and concentrations of serum adiponectin were measured before, during and 1 month after the treatment by a euglycaemic–hyperinsulinaemic clamp and ELISA, respectively.

Results

There was a reversible reduction in whole-body insulin sensitivity during therapy with 13-cis-retinoic acid. This was associated with a transient 34% increase in serum adiponectin concentration (from 5.3±0.9 to 7.1±1.2 μg/ml, p<0.05), with a return to pretreatment levels by 1 month after the end of therapy. In the pretreatment study, as well as in the study performed 1 month after the end of therapy, there was a small yet significant decrease in serum adiponectin concentration during a 4-h euglycaemic–hyperinsulinaemic clamp. This decrease was not observed in the clamp performed during treatment with 13-cis-retinoic acid.

Conclusions/interpretation

There is a paradoxical increase in fasting serum adiponectin concentration during the 13-cis-retinoic acid-induced reduction in insulin sensitivity.
Literature
1.
2.
go back to reference Kliewer SA, Xu HE, Lambert MH, Wilson TM (2001) Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56:239–263PubMedCrossRef Kliewer SA, Xu HE, Lambert MH, Wilson TM (2001) Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56:239–263PubMedCrossRef
3.
go back to reference Koistinen HA, Remitz A, Gylling H, Miettinen TA, Koivisto VA, Ebeling P (2001) Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diabetes Metab Res Rev 17:391–395PubMedCrossRef Koistinen HA, Remitz A, Gylling H, Miettinen TA, Koivisto VA, Ebeling P (2001) Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diabetes Metab Res Rev 17:391–395PubMedCrossRef
4.
go back to reference Yu JG, Javorschi S, Hevener AL et al (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974PubMedCrossRef Yu JG, Javorschi S, Hevener AL et al (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974PubMedCrossRef
5.
go back to reference Hulver MW, Zheng D, Tanner CJ et al (2002) Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 283:E861–E865PubMed Hulver MW, Zheng D, Tanner CJ et al (2002) Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 283:E861–E865PubMed
6.
go back to reference Ramsay JE, Jamieson N, Greer IA, Sattar N (2003) Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension 42:891–894PubMedCrossRef Ramsay JE, Jamieson N, Greer IA, Sattar N (2003) Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension 42:891–894PubMedCrossRef
7.
go back to reference Iwaki M, Matsuda M, Maeda N et al (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655–1663PubMedCrossRef Iwaki M, Matsuda M, Maeda N et al (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655–1663PubMedCrossRef
8.
go back to reference Zhang Y, Matheny M, Zolotukhin S, Tumer N, Scarpace PJ (2002) Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of β3-adrenergic agonists, retinoic acid, leptin and fasting. Biochim Biophys Acta 1584:115–122PubMed Zhang Y, Matheny M, Zolotukhin S, Tumer N, Scarpace PJ (2002) Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of β3-adrenergic agonists, retinoic acid, leptin and fasting. Biochim Biophys Acta 1584:115–122PubMed
9.
go back to reference Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC (1997) Current use and future potential role of retinoids in dermatology. Drugs 53:358–388PubMedCrossRef Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC (1997) Current use and future potential role of retinoids in dermatology. Drugs 53:358–388PubMedCrossRef
10.
go back to reference Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356–362PubMedCrossRef Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356–362PubMedCrossRef
Metadata
Title
Paradoxical rise in serum adiponectin concentration in the face of acid-induced insulin resistance 13-cis-retinoic
Authors
H. A. Koistinen
A. Remitz
V. A. Koivisto
P. Ebeling
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0089-z

Other articles of this Issue 2/2006

Diabetologia 2/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine